Get our latest issue now

available for iOS, Android & web

latest issue

Elan to bank $381 million from sale of Alkermes stock

Daily News | March 14, 2012

Kevin Grogan

Elan to bank $381 million from sale of Alkermes stock

Elan Corp is set for a windfall after selling a major part of its stake in fellow Ireland-headquartered firm Alkermes.

Last September, Alkermes finalised its purchase of Elan Drug Technology in a cash and stock transaction, valued at $960 million, saw Elan receive $500 million in cash and nearly 32 million shares, or a 25% stake in the newly-created Alkermes business. Now it has decided to cash in some of the stock, almost 24.2 million shares.

That corresponds to 76% of Elan's shareholding, bringing in proceeds of around $381 million. The company is keeping hold of almost 7.8 million shares, equating to a stake in Alkermes of just under 6%.

Elan says that the funds will be used to further strengthen its cash balances and capital structure. Alkermes did not receive any proceeds from the offering.

File for Megestrol Alkermes pulled in Europe

Staying with Alkermes, and the European Medicines Agency reports that the company has decided to withdraw its application for a centralised marketing authorisation for Megestrol Alkermes (megestrol), 125 mg/ml oral suspension.

Megestrol Alkermes was intended to be used for the treatment of anorexia, cachexia or an unexplained significant weight loss in adult AIDS and oncology patients. However, the company has told the EMA that it has pulled the file "as a consequence of portfolio prioritisation".

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!


Most read articles

Latest Jobs